Table 1.
Patient characteristics, toxicities, and response to therapy
| Patient code | Age | Sex | Stage | Disease sites | Prior therapy | Tremelimumab doses, no. | Treatment-related toxicity, G2/G3 | Best response |
| 1103 | 80 | M | IVc | Liver | 2 | Diarrhea G2 | PD | |
| Lung | ||||||||
| 1104 | 63 | M | IVb | LN | Temozolomide, thalidomide, IL-2 | 2 | PD | |
| Lung | ||||||||
| Liver | ||||||||
| Adrenal | ||||||||
| Kidney | ||||||||
| 1105A | 61 | M | IVc | LN | Cisplatin, vinblastine, temozolomide, IL-2, IFN, lenalidomide, MART1/DC | 11 | Hepatitis G3 Acne Rosacea G2 | SD × 11 mos |
| Lung | ||||||||
| Stomach | ||||||||
| 1105P | 55 | F | IVc | LN | Cisplatin, vinblastine, dacarbazine, paclitaxel, gefitinib, BCG, IL-2, IFN | 4 | PD | |
| Lung | ||||||||
| Liver | ||||||||
| 1106 | 52 | F | IVc | LN | Cisplatin, vinblastine, dacarbazine | 4 | Diarrhea G3 Rash G2 | PD |
| Lung | ||||||||
| Liver | ||||||||
| 1107 | 57 | M | IVc | LN | Heat shock | 2 | PD | |
| Liver | Protein | |||||||
| 1108 | 55 | F | IIIc | SC | GM-CSF | 5 | Hepatitis G3 Hypophysitis G2 | CR × 39+ mo. |
| LN | ||||||||
| 1109 | 54 | M | IVa | LN | ILX 651 | 3 | Leuko-cytoclastic vasculitis G3 | PD |
| 1110 | 34 | M | IVa | SC | IL-2 | 3 | PD | |
| LN | ||||||||
| 1111 | 90 | M | IIIc | Skin | BCG, | 8 | Diarrhea G2 | PR × 34+ mo. |
| LN | AMG 706 | |||||||
| 1113 | 63 | M | IVa | LN | IFN | 22 | Hypophysitis G2 Elevated trans-aminases G2 Asthenia G2 Arthralgia G2 Grover's G2 Uveitis G2 | pPR × 33+ mo. |
| 1114 | 61 | M | IVa | LN | IFN, temozolomide | 2 | Colitis G3 | SD × 8 mo. |
No. = Number; G = Grade; M = Male; PD = Progressive disease; LN = Lymph node; IL-2 = Interleukin-2; SD = Stable disease; mo.= Months; IFN = Interferon; MART1 = Melanoma-associated antigen recognized by T cells; DC = Dendritic cells; F = Female; BCG = Bacillus Calmette-Guérin; SC = Subcutaneous; GM-CSF = Granulocyte-macrophage colony-stimulating factor; CR = Complete response; PR = Partial response; pPR = Pathological partial response.